Biomet is now Zimmer Biomet

Background Image

Biomet announces aquisition of the assets of cartilage repair company Cartilix
October 20, 2009

Warsaw, IN, October 20, 2009—Biomet, Inc., a global leader in the manufacture of orthopedic and dental medical devices, announced today its acquisition of the assets of Cartilix, a Foster City, CA based company that has developed proprietary cartilage repair technology. Cartilix was founded in 2004 to develop cartilage repair and regeneration solutions. The company developed ChonDux™, a proprietary cartilage regeneration technology for repair of knee cartilage. ChonDux™ technology uses a biological adhesive and hydrogel to fill articular cartilage lesions.

ChonDux™ technology is not yet commercially available. Clinical trials are scheduled to begin in Europe during the first half of 2010 with a U.S. clinical trial anticipated to follow thereafter. Jeff Binder, Biomet President and CEO, stated: “We believe that Cartilix’s technology platform is a great fit for Biomet’s continuum of solutions for knee disorders. Biomet has a rapidly-growing sports medicine franchise, the world’s leading partial knee replacement system, and the most comprehensive total knee replacement system on the market, allowing us to provide a broad spectrum of solutions for varying degrees of knee disorders. The Cartilix technology provides Biomet with an opportunity to facilitate earlier intervention in pre-arthritic patients.”

About Biomet

Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. Biomet’s product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, autologous therapies and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in approximately 90 countries.

For more information, please contact:
Ross Erickson
Vice President of Strategic Clinical Research and Regulatory Affairs
Biomet, Inc.

© Copyright 2021 Biomet, Inc. All rights reserved.
Background Image